IP Verse

Astellas Pharma Inc. opposition analysis

COMPANY ANALYSIS

Latest patents of Astellas Pharma Inc. opposed by its competitors

Patent:
EP3318259
Grant Date:
Jan 11, 2023
Title:
Stable Pharmaceutical Composition For Oral Administration
Oppositions:
2
Patent:
EP3725810
Grant Date:
Jul 6, 2022
Title:
Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer
Oppositions:
2
Patent:
EP3725778
Grant Date:
Aug 18, 2021
Title:
Formulations Of Enzalutamide
Oppositions:
11
Patent:
EP2345410
Grant Date:
Dec 30, 2020
Title:
Controlled Release Pharmaceutical Composition
Oppositions:
6
Patent:
EP3254695
Grant Date:
Sep 9, 2020
Title:
Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer
Oppositions:
1
Patent:
EP2824181
Grant Date:
Nov 14, 2018
Title:
Novel Fgfr3 Fusion Product
Oppositions:
2
Patent:
EP2554168
Grant Date:
Jan 24, 2018
Title:
Controlled Release Pharmaceutical Composition
Oppositions:
4

Competitors of Astellas Pharma Inc.

SANDOZ AG

ALFRED E. TIEFENBACHER (GMBH & CO. KG)

BULLE DR., JAN

Want to track Astellas Pharma Inc.?

Feel free to send us a message here and we will get back to you